The result arrives materially ahead of the expected timetable. Cullinan and Taiho had previously guided to REZILIENT3 topline results by the end of 2026, so an interim PFS readout on August 12, 2026 is earlier than the standing milestone.
The trial cleared its core success test. In the 285-patient Phase 3 study, zipalertinib plus platinum chemotherapy produced a statistically significant and clinically meaningful PFS improvement versus chemotherapy alone at planned interim analysis, prompting the independent monitoring committee to recommend unblinding. The trial continues for further efficacy and safety follow-up. (About the REZILIENT3 Trial)
This is better than a mere “trial ongoing” update, but the filing withholds the numbers that determine magnitude. It provides no hazard ratio, median PFS, confidence interval, overall-survival result, or detailed adverse-event table. “Manageable” safety is encouraging but cannot yet establish how the regimen compares on tolerability. (REZILIENT3 topline results)
Net read: above the clinical bar and meaningfully de-risks the first-line opportunity. The positive interim result supports plans to pursue U.S. approval for the combination, but the investment case still depends on the full dataset, regulatory feedback, and whether the eventual PFS benefit is large and durable enough to change treatment practice. (REZILIENT3 topline results)
Read the original 8-K on SEC EDGAR ↗